GLP-1
44 quarters of ground truth.
This is what IMX Data sees — and what it means for you.
Press arrow keys, space, or Enter to advance
Aggregated averages hide critical variation in state-by-state adoption, spend, and payer mix.
By the time public data surfaces, the market has moved. Competitors have already repositioned.
Piecing together demographics, drug mix, and geography means months of reconciliation with no single truth.
The global obesity GLP-1 market is projected to grow at roughly 23% CAGR, with shortages driving multi-billion-dollar manufacturing build-outs. The IMX claims layer is where those macro forces show up as state, payer, and drug-level reality.
U.S. GLP-1 claim volume grew 3,498% from our 2015 baseline to today. Every quarter without granular intelligence, you are navigating the fastest-moving drug class in history — blindfolded.
External market context (2024–2025): Industry reporting attributes roughly $31.1B combined 2024 revenue to Novo Nordisk’s semaglutide franchise (Ozempic, Wegovy, Rybelsus) and $16.5B combined to Lilly’s tirzepatide brands (Mounjaro about $11.5B; Zepbound about $4.9B). By Q3 2025, tirzepatide products had passed $10B in combined quarterly revenue in company reports. These figures anchor why IMX manufacturer and drug mix trends matter.
The spend story is as dramatic as the claims story — but the composition matters. Plan pay has surged while patient out-of-pocket compresses, reflecting insurer adoption waves and manufacturer coupon programs.
The signal: When patient OOP flattens while plan pay accelerates, it marks an insurer coverage wave — visible in IMX data quarters before analyst reports catch up.
IMX national roll-up: quarterly market spend first crosses $5.2B in Q4 2021 ($5.24B vs $3.70B in Q3 2021).
IMX aggregates, normalizes, and delivers U.S. pharmaceutical claims at a depth no other provider matches — state-level, quarter-by-quarter, segmented by drug, payer, demographics, and geography.
All 54 U.S. jurisdictions in the extract. Real prescribing behavior, state by state, every quarter — not national averages.
2015–2025. Every inflection point, every policy shock, every drug launch is visible in the data.
Ozempic vs. Wegovy vs. Mounjaro vs. Zepbound — claims, spend, and share broken out by drug.
Medicare, Medicaid, PBM, Commercial, Cash — each tracked separately, every single quarter.
Age cohorts, gender — every dimension needed to model real patient populations with precision.
National averages mask enormous state-to-state variation. IMX Data delivers prescribing intelligence at the state level (even as granular as Zip level) — identify where adoption is accelerating, where payers are resisting, where the next opportunity is forming.
Real insight: When Zepbound received FDA approval, IMX Data revealed which states adopted within the first quarter vs. those lagging 6+ months — exposing physician network dynamics invisible nationally.
54 jurisdictions tracked. Every adoption curve, every payer shift — visible as it happens.
IMX tracks every drug on a daily basis. Sponsor trial narratives (previous slide) should reconcile with claim volume and share on this view — when they diverge, you have an investable dislocation.
IMX Data separates Medicare, Medicaid, Commercial, PBM, and Cash-pay volumes. The cash-pay segment alone tells you more about pricing strategy than any analyst report.
98.7% of spend is covered by payers — but the cash-pay trajectory is the most direct signal for oral GLP-1 pricing. IMX tracks it daily.
Compounded GLP-1s: Industry analyses tie the majority of compounded GLP-1 volume to weight-management use; utilization via telehealth and direct channels often stayed elevated even after national shortage flags for innovator products eased. IMX separates branded, covered volume from cash and alternative pathways — critical when assessing true branded demand.
The 1960s birth decade leads with 4.9M claims — the highest-volume segment. Oral GLP-1 penetration into younger cohorts is the #1 thesis to validate in upcoming quarters.
Novo Nordisk expects oral GLP-1 obesity medicines to take a materially larger share by 2030 than older forecasts implied — including among men and younger patients paying out of pocket. Phase 3 OASIS 4 reported about 16.6% mean weight loss at 64 weeks in treatment-adherent adults (oral semaglutide 25 mg vs placebo), with an intention-to-treat average near 13.6%. The FDA approved oral semaglutide 25 mg as Wegovy in December 2025 (empty stomach, 30 minutes before food or other oral meds); list pricing near $149/month in company communications.
Why it matters: Oral uptake — cash-pay, younger, male — is trackable in IMX demographics and payer mix. Lilly’s oral orforglipron (ATTAIN / ACHIEVE) is a separate adherence story: no food/water restriction, with maintenance data after switching from injectables.
IMX Data is the early warning system. Every policy shift, every approval, every pricing change — you'll see its footprint in claims data before it becomes consensus. 44 quarters of proof.
IMX Data delivers the depth behind the headlines.
Every drug · Every state · Every day.